J Breast Cancer.  2009 Dec;12(4):235-240. 10.4048/jbc.2009.12.4.235.

Comparison of Silver-Enhanced in situ Hybridization and Fluorescence in situ Hybridization for HER2 Gene Status in Breast Carcinomas

• Kang J
• Kwon GY
• Lee YH
• Gong G

• KMID: 2175512
• DOI: http://doi.org/10.4048/jbc.2009.12.4.235

Abstract

PURPOSE
Silver-enhanced in situ hybridization (SISH) is a newly developed method to evaluate HER2 gene amplification in invasive breast carcinomas. Most laboratories widely use fluorescence in situ hybridization (FISH) to evaluate the HER2 gene amplification status because FISH is a very sensitive and accurate technique. However, this technique is not the best because it requires specialized equipment and interpretation skills. We compared a new technique of SISH with FISH for assessing HER2 gene amplification in invasive breast carcinomas. METHODS: HER2 gene amplification was assessed in 165 cases of invasive breast carcinoma by FISH and SISH with constructing a tissue microarray. The tumors were assessed by the guidelines of the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP). Positivity was defined as a HER2/Chromosome 17 ratio greater than 2.2. Negativity was defined if the ratio was less than 1.8. The tumor was considered as equivocal for HER2 gene amplification if the ratio was between 1.8 and 2.2. The HER2 protein status was assessed. Immunostaining for HER2 protein was performed in a Benchmark automatic immunostaining device with using whole tissue sections. RESULTS: There was agreement of the HER2 gene amplification status by SISH and FISH in 162 of 165 cases, which is a concordance rate of 98.2% (kappa=0.94). There were three discrepant cases, with two of them being FISH positive and SISH negative (one case was IHC negative and one case was IHC positive) and one case was FISH negative and SISH equivocal. CONCLUSION: The 98.2% concordance between FISH and SISH meets the ASCO/CAP requirements for test validation of >95% concordance. These results indicate that SISH can be used as an alternative to FISH for assessing the HER2 gene amplification status in breast carcinomas.

Keyword

Breast neoplasms; erbB-2 receptor; In Situ Hybridization

MeSH Terms

Breast
Breast Neoplasms
Fluorescence
Genes, erbB-2
In Situ Hybridization
Receptor, erbB-2
Receptor, erbB-2

Figure

• 

  Figure 1 Typical example of a non-amplified case and amplified case as demonstrated by Silver-enhanced in situ hybridization (SISH). (A) Two single dots represent each Chr17, (B) non-amplified HER2 case showed 2 HER2 signals in tumor cells (arrow), (C) amplified HER2 case showed clusters of HER2 signals in tumor cells (arrow). Note the fibroblasts (arrow head) as internal control (×1,000).

Reference

1. Sahin AA. Biologic and clinical significance of HER2/neu (cerbB-2) in breast cancer. Adv Anat Pathol. 2000. 7:158–166.

2. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999. 17:2639–2648.

3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001. 344:783–792.

4. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008. 112:533–543.

5. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006. 355:2733–2743.

6. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007. 25:118–145.

7. Dowsett M, Hanna WM, Kockx M, Penault-Llorca F, Rüschoff J, Gutjahr T, et al. Standardization of HER2 testing: results of an international proficiency-testing ring study. Mod Pathol. 2007. 20:584–591.

8. Cell Markers and Cytogenetics Committees College Of American Pathologists. Clinical laboratory assays for HER2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing. Arch Pathol Lab Med. 2002. 126:803–808.

9. Dietel M, Ellis IO, Höfler H, Kreipe H, Moch H, Dankof A, et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch. 2007. 451:19–25.

10. Carbone A, Botti G, Gloghini A, Simone G, Truini M, Curcio MP, et al. Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists. J Mol Diagn. 2008. 10:527–536.

11. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996. 13:63–72.

12. Hauser-Kronberger C, Dandachi N. Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer. J Mol Histol. 2004. 35:647–653.

13. Gupta D, Middleton LP, Whitaker MJ, Abrams J. Comparison of fluorescence and chromogenic in situ hybridization for detection of HER2/neu oncogene in breast cancer. Am J Clin Pathol. 2003. 119:381–387.